Patents for A61P 35 - Antineoplastic agents (221,099)
08/2002
08/08/2002WO2002060456A1 Treatment of angiogenesis-dependent conditions with dextrin sulphates
08/08/2002WO2002060455A1 Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation
08/08/2002WO2002060453A1 Remedies for lung cancer
08/08/2002WO2002060450A1 Pyrimidine compounds and methods for making and using the same
08/08/2002WO2002060449A2 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
08/08/2002WO2002060447A1 Receptor selective cannabimimetic aminoalkylindoles
08/08/2002WO2002060438A1 Substituted indoles and their use as integrin antagonists
08/08/2002WO2002060436A2 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states
08/08/2002WO2002060434A2 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
08/08/2002WO2002060426A2 Compounds regulating cell proliferation and differentiation
08/08/2002WO2002060412A2 Stabilised polymeric aerosols for pulmonary gene delivery
08/08/2002WO2002060411A2 Process for production of nanoparticles and microparticles by spray freezing into liquid
08/08/2002WO2002060388A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
08/08/2002WO2002060383A2 Cancer therapy
08/08/2002WO2002060382A2 Novel compounds and uses thereof
08/08/2002WO2002060378A2 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
08/08/2002WO2002060375A2 Diphenyl ether derivatives and their uses as heparanase inhibitors
08/08/2002WO2002060374A2 Benz-1,3-azole derivatives and their uses as heparanase inhibitors
08/08/2002WO2002060373A2 Indole derivatives and their uses as heparanase inhibitors
08/08/2002WO2002060276A1 Combination of probiotics
08/08/2002WO2002040505A3 Dibenzoxazepine alpha v integrin receptor antagonist
08/08/2002WO2002038541A9 Cyanopyrrolidine derivatives
08/08/2002WO2002034716A3 Pyrrolidine modulators of ccr5 chemokine receptor activity
08/08/2002WO2002032900A3 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
08/08/2002WO2002032409A3 Use of compound in the manufacture of a pharmaceutical for inhibiting steroid sulphatase and steroid dehydrogenase activity
08/08/2002WO2002030455A3 Agents for the treatment of viral infections
08/08/2002WO2002028165A3 Compositions and methods of using capsid protein from flaviviruses and pestiviruses
08/08/2002WO2002026192A3 Viruses targeted to hypoxic cells and tissues
08/08/2002WO2002022175A3 Method and composition for treating tumors by selective induction of apoptosis
08/08/2002WO2002022161A3 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases
08/08/2002WO2002020762A3 Tnf receptor-like molecules and uses thereof
08/08/2002WO2002018582A3 62112, a novel human dehydrogenase and uses thereof
08/08/2002WO2002015722A3 Treatment of helicobacter with isothiocyanates
08/08/2002WO2002014347A3 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
08/08/2002WO2002011747A3 Transglutaminase for inhibiting angiogenesis
08/08/2002WO2002010140A3 Imidazolyl derivatives
08/08/2002WO2002009690A3 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
08/08/2002WO2002006189A3 Aniline derivatives
08/08/2002WO2002000840A3 Human lyases
08/08/2002WO2002000194A3 Polymeric micelle compositions
08/08/2002WO2002000170A3 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
08/08/2002WO2001098268A3 Piperidine amides as modulators of chemokine receptor activity
08/08/2002WO2001097858A3 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
08/08/2002WO2001096546A3 Protein phosphatases
08/08/2002WO2001095934A3 The use of plant oil-bodies in vaccine delivery systems
08/08/2002WO2001095917A3 Kefir extract as an anti-cancer agent
08/08/2002WO2001095899A3 Pharmaceutical compositions comprising cannabidiol derivatives
08/08/2002WO2001094312A3 Indolinone derivatives as protein kinase/phosphatase inhibitors
08/08/2002WO2001093840A3 Ligands of integrin receptors
08/08/2002WO2001092522A3 Human fgf-20 nucleic acids and polypeptides
08/08/2002WO2001092306A3 Therapeutic compounds for ovarian cancer
08/08/2002WO2001092295A3 Ligands for cd21 and compositions thereof for modulating immune responses
08/08/2002WO2001090361A3 Modulation of inflammation by protease-treated mcp-3 chemokine
08/08/2002WO2001090330A3 AMINOACYL tRNA SYNTHETASES
08/08/2002WO2001087935A3 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
08/08/2002WO2001085784A9 POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF
08/08/2002WO2001085212A3 Drug delivery systems for photodynamic therapy
08/08/2002WO2001082907A3 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
08/08/2002WO2001081585A3 A thymus expressed human cytochrome p450 (p450tec)
08/08/2002WO2001081312A3 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
08/08/2002WO2001080890A3 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
08/08/2002WO2001077376A3 Diagnosis of diseases associated with metastasis
08/08/2002WO2001076451A9 Diagnosis of diseases associated with metabolism
08/08/2002WO2001070941A3 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
08/08/2002WO2001051641A9 Irak-4: compositions and methods of use
08/08/2002WO2001051523A3 Anti-angiogenic proteins and fragments and methods of use thereof
08/08/2002WO2001048238A3 Chemotherapeutant screening method
08/08/2002WO2001034802A9 Compositions and methods for the therapy and diagnosis of prostate cancer
08/08/2002WO2001032925A9 Modulation of neuroendocrine differentiation by protein 25.1
08/08/2002WO2001021799A9 Traf4 associated cell cycle proteins, compositions and methods of use
08/08/2002WO2001013714A3 Prostatic cell line and animal model of a prostatic tumor
08/08/2002WO2001009325A9 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations
08/08/2002WO2001009090A3 Hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
08/08/2002WO2001008636A8 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
08/08/2002US20020107869 Novel implant and novel vector for the treatment of acquired diseases
08/08/2002US20020107404 Sulfur-containing indirubin derivatives, their production and use
08/08/2002US20020107400 Cyanoguanidines as cell proliferation inhibitors
08/08/2002US20020107393 The crystalline monohydrate form provides increased stability over the anhydrous form.
08/08/2002US20020107392 Quinolinone derivatives
08/08/2002US20020107385 Human breast tumor-specific proteins
08/08/2002US20020107370 Protein for use in the treatment of lzheimer's, parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, retinopathy, brain, blood, myocardium, stroke, reperfusion injury and liver disorders
08/08/2002US20020107363 B7-Like molecules and uses thereof
08/08/2002US20020107284 Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
08/08/2002US20020107276 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
08/08/2002US20020107274 Potent inhibitors of cyclin dependent kinases; treating cancer or other proliferative diseases
08/08/2002US20020107273 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
08/08/2002US20020107269 Inhibiting cell proliferation and treating cancer
08/08/2002US20020107262 Substituted imidazopyridines
08/08/2002US20020107255 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
08/08/2002US20020107251 4-(hetero)aryl-3-oxo-3,4-dihydropyrido(2,3-b)pyrazine derivatives; prophylactic or therapeutic treatment of phosphodiesterase IV and tumor necrosis factor mediated diseases
08/08/2002US20020107237 Topoisomerase inhibitors
08/08/2002US20020107234 Lipoic acid derivatives and their use in treatment of disease
08/08/2002US20020107225 Use of nucleoside analogues (cytosine or 5-fluorocytosine containing compound) useful for acute or chronic myelogenous leukemia
08/08/2002US20020107224 Used as anti-tumor agents and/or anti-HIV agents having immunostimulate activities; inversion of OR2 to OR1 in glucopyranose derivtives (R1= H or acetyl, R2= a leaving group such as tosylate, trifluoromesylate or methanesulfonate
08/08/2002US20020107218 Using inhibitors such as antisense nucleic acids
08/08/2002US20020107197 Ligands for G protein coupled receptors and methods of using them
08/08/2002US20020107194 Able to bind to a Notch protein forming Delta-Notch complex
08/08/2002US20020107180 Cell surface glycoproteins
08/08/2002US20020106796 PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof
08/08/2002US20020106780 Extracellular matrix polynucleotides, polypeptides, and antibodies